CURNZ Stock Overview
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Curatis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 6.94 |
| 52 Week High | CHF 14.90 |
| 52 Week Low | CHF 5.10 |
| Beta | 0 |
| 11 Month Change | 30.94% |
| 3 Month Change | 2.66% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| CURNZ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -49.3% | -1.9% | -0.5% |
| 1Y | n/a | 4.9% | 7.9% |
Return vs Industry: Insufficient data to determine how CURNZ performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CURNZ performed against the UK Market.
Price Volatility
| CURNZ volatility | |
|---|---|
| CURNZ Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: CURNZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CURNZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Roland Rutschmann | curatis.com |
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington’s disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases.
Curatis Holding AG Fundamentals Summary
| CURNZ fundamental statistics | |
|---|---|
| Market cap | CHF 30.70m |
| Earnings (TTM) | CHF 0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CURNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 0 |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 0 |
| Other Expenses | CHF 0 |
| Earnings | CHF 0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CURNZ perform over the long term?
See historical performance and comparison